ESMO 2025 Update: Effect of Abemaciclib added to standard Endocrine Therapy in High-Risk Early Breast Cancer
Adjuvant abemaciclib combined with endocrine therapy (ET) has demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with standard ET in patients with hormone receptor–positive (HR+),…